Homology Medicines Liabilities 2024

Homology Medicines Aktienanalyse

What does Homology Medicines do?

Homology Medicines Inc. is a US-based company focused on the development of gene therapy technologies. The company was founded in 2015 and is headquartered in Bedford, Massachusetts. Homology Medicines Inc. aims to develop and market innovative gene therapies for rare diseases and genetic disorders. The company's goal is to develop new therapies through gene editing that can specifically modify genes to treat or alleviate symptoms of diseases. Homology Medicines bases its methodology on the natural processes of viral transport, through which double-stranded DNA is anchored into the cell. This allows the DNA to be directly introduced into living tissue, where it has systemic effects. Homology's gene therapy technology is based on the recombination of adenoviral vectors. The business model of Homology Medicines is to develop and market innovative gene therapies for rare diseases and genetic disorders. The company focuses on close collaboration with clinics to make the new therapies quickly and efficiently available to patients. The company has a close partnership with the National Institute of Health (NIH) to utilize its technology for gene therapy of rare diseases and genetic disorders. Homology Medicines Inc. specializes in three different branches of gene therapy: 1. In vivo gene therapy: In this method, gene therapies are directly introduced into the patient's tissue. Homology Medicines is working on developing new efficient methods for virus transport of therapeutics into the central nervous system and cardiovascular tissue. These methods aim to minimize the occurrence of unwanted effects. 2. Ex vivo gene therapy: In ex vivo gene therapy, a patient's cells are taken, modified, and then reintroduced into the patient. This method is particularly relevant for immune system disorders and cancer treatments. Homology Medicines is working on new efficient methods for the transport of modifiers into cells. 3. Genome editing therapy: In this final branch, Homology Medicines is working on developing genome editors that are specifically designed for defective genes. The technology is intended for the treatment of genetic diseases and restoring the functionality of defective genes. Homology Medicines Inc. is known for its low costs in gene therapy development. By utilizing natural viral transport methods and closely analyzing defects in humans, the company is able to quickly and cost-effectively develop therapies for patients. The company has already initiated several successful developments in gene therapy and continues to seek new innovations and developments to better meet the needs of patients. Homology Medicines ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Homology Medicines's Liabilities

Homology Medicines's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Homology Medicines's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Homology Medicines's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Homology Medicines's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Homology Medicines’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Homology Medicines stock

What is the level of liabilities of Homology Medicines this year?

Homology Medicines has a debt balance of 11.57 M USD this year.

What were the liabilities of Homology Medicines compared to the previous year?

The liabilities of Homology Medicines have increased by -77.08% dropped compared to the previous year.

What are the consequences of high debt for investors of Homology Medicines?

High liabilities can pose a risk for investors of Homology Medicines, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Homology Medicines?

Low liabilities mean that Homology Medicines has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Homology Medicines affect the company?

An increase in liabilities of Homology Medicines can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Homology Medicines affect the company?

A decrease in the liabilities of Homology Medicines can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Homology Medicines?

Some factors that can influence the liabilities of Homology Medicines include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Homology Medicines so important for investors?

The liabilities of Homology Medicines are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Homology Medicines take to modify the liabilities?

To change its liabilities, Homology Medicines can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Homology Medicines pay?

Over the past 12 months, Homology Medicines paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Homology Medicines is expected to pay a dividend of 0 USD.

What is the dividend yield of Homology Medicines?

The current dividend yield of Homology Medicines is .

When does Homology Medicines pay dividends?

Homology Medicines pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Homology Medicines?

Homology Medicines paid dividends every year for the past 0 years.

What is the dividend of Homology Medicines?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Homology Medicines located?

Homology Medicines is assigned to the 'Health' sector.

Wann musste ich die Aktien von Homology Medicines kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Homology Medicines from 10/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/7/2024.

When did Homology Medicines pay the last dividend?

The last dividend was paid out on 10/7/2024.

What was the dividend of Homology Medicines in the year 2023?

In the year 2023, Homology Medicines distributed 0 USD as dividends.

In which currency does Homology Medicines pay out the dividend?

The dividends of Homology Medicines are distributed in USD.